Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2015-04-30 Board/Management Inform…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2015, reporting the election of a new director, John Sexton, Ph.D., to the company's Board of Directors. It details his background, the terms of his appointment, stock option grants, and indemnification agreement. The key section is Item 5.02, which relates to the departure and election of directors and officers. There is no financial data or earnings information, nor is this a report or announcement of a report publication. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2015-04-30 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated April 29, 2015, reporting the election of a new director, John Sexton, Ph.D., to the company's Board of Directors. It details his background, the terms of his appointment, stock option grants, and indemnification agreement. The key section is Item 5.02(b), (d), and (e), which relates to the departure and election of directors and officers. There is no financial data or earnings information, nor is this a proxy solicitation or voting results announcement. The document is clearly an announcement of changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6424 characters) supports it being a full announcement rather than a brief notice or report publication announcement. Confidence is high given the explicit content and SEC form type.
2015-04-30 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy statement. It includes information about the annual meeting, voting instructions, director nominations, and auditor ratification. It is not the actual annual report or financial statements but rather materials sent to shareholders to provide information and solicit votes for the meeting. Therefore, it fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is over 6000 characters, indicating it is substantive proxy materials, not just a brief announcement.
2015-04-20 English
DEF 14A
Proxy Solicitation & Information Statement
2015-04-20 English
FORM 4 -
Director's Dealing
2015-04-14 English
FORM 4 -
Director's Dealing
2015-04-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.